Institutes: Ukrainian Medical and Dental Academy, Regional HIV/AIDS Prevention and Control Center, Poltava Ukraine Toll-like receptor 4 polymorphism influence.

Slides:



Advertisements
Similar presentations
BORDERNETwork Training on Late Presenter Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
Advertisements

Module 1: Overview of HIV Infection Unit 01.03: Natural History and Progression Of HIV Infection 1.
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
HIV 101 Review Evaluation Center for HIV and Oral Health Boston University School of Public Health Health & Disability Working Group.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Roundtable Presentation S Tripathy National AIDS Research Institute 73 G Block, MIDC Bhosari, Pune , India.
HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,
Immunodeficiencies HIV/AIDS. Immunodeficiencies Due to impaired function of one or more components of the immune or inflammatory responses. Problem may.
Diagnostic testing for HIV: The symptomatic patient.
Adapted from curriculum by Tucson Interfaith HIV/AIDS Network
What is HIV ? H- Human I- Immunodeficiency V- Virus Only transferrable between humans Weakens immune system by destroying cells that fight disease= “deficient”
Natural History and Clinical Staging of HIV Training for Medical Officers Day 2 Session 7.
Chronic HIV Infection Clinical Manifestations Opportunistic Infections O.I. Prophylaxis.
HIV and AIDS: Protecting Yourself, Protecting Others David Lee, Mollie Williams, and Andrew Frankart.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
HIV/AIDS. HIV/AIDS Vocabulary HIV Human (only in humans) Immune (fights infections) deficiency (lack something) Virus (infection that cannot be cured)
H.I.V./ A.I.Ds ..
INDIA and HIV/AIDS Student Example 2009 Comprehensive Health Education.
Washington D.C., USA, July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong,
VIRUSES. Lytic vs. Lysogenic Vaccines First made was in 1700’s- fight smallpox Help prevent viral infections, but they cannot cure most viral infection.
Immunology, the HIV life cycle and stages of infection Anele Waters HIV Research Nurse North Middlesex Hospital, London.
Promoter polymorphism of macrophage Migration Inhibitory Factor (MIF) gene in Czech and Russian patients with myocardial infarction Promoter polymorphism.
Classification of HIV and Expanded AIDS Surveillance Case Definition.
Affordable healthcare Product Selection for Opportunistic Infections IDA HIV/AIDS Group, Nienke Gruppelaar “ HIV does not kill, opportunistic infections.
PMTCT Generic Training PackageModule 1Slide 1 Introduction to HIV/AIDS M O D U L E 1.
HIV/AIDS: An Overview Andrea A. Howard, MD, MS Montefiore Medical Center.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
1 Natural Course of HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Clinical Care of HIV, AIDS and Opportunistic Infections
Increased clinical events in HIV-infected patients who achieve full virologic suppression but fail to attain a CD4 count ≥ 200 cells/mm 3 after one year.
Ukrainian TB mortality assessment 2008: Low HIV awareness and access to ART for TB patients associated with high HIV related TB mortality Presenting author:
Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,
Association between CSF and peripheral markers of immune- activation/inflammation and elevated intratechal HIV–RNA levels in a cohort of.
Arnold School of Public Health Health Services, Policy, and Management 1 Drug Treatment Disparities Among African Americans Living with HIV/AIDS Carleen.
Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.
Press Briefing: Office of the Vice Chancellor MUK 6 th September 2010 The Infectious Diseases Institute Care and Research Initiatives Dr Alex G Coutinho.
1 HIV Clinical Staging HAIVN Harvard Medical School AIDS Initiative in Vietnam.
HIV-1 infection decreases CD127 and PD1 expression on duodenal CD8+T cells Liliana Belmonte, PhD Academia Nacional de Medicina Buenos Aires, Argentina.
Human Immunodeficiency Virus (HIV) This virus causes HIV infection and AIDS The HIV infected person may, or may not have AIDS. They may, or may not, have.
Prophylaxis of Opportunistic Infections
HIV and AIDS PM2 PATHOPHYSIOLOGY. HIV is the causative agent of AIDS Human immunodeficiency virus Human immunodeficiency virus retrovirus retrovirus most.
Polymorphisms in the CRP and C1 Q genes and schizophrenia in Armenian population: A pilot study Zakharyan R 1,2, Khoyetsyan A 1, Chavushyan A 1, Arakelyan.
Human Immunodeficiency Virus & Acquired Immunodeficiency Syndrome Community Medicine - Reporting October 10, 2011.
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1 infected naïve patients with high CD4 counts Viral tropism by geno2pheno as.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Interventions for Clients with HIV/AIDS and Other Immunodeficiencies.
Chapter 5: The Medical Side of Living with HIV/AIDS.
ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.
Provider Initiated HIV Counseling and Testing Unit 1: Introduction to HIV/AIDS.
Conclusions: Results : Methods: We prospectively recruited 50 women with recurrent pregnancy loss mean age 33.0 (±5.4) years and 30 healthy controls mean.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
1 Predictors of virological failure in a Cambodian setting Sokkab An, M.D Sihanouk Hospital Center of HOPE (SHCH), Phnom Penh, Cambodia.
Initiative taken by Health Camp
Effects of daily trimethoprim-sulfamethoxazole prophylaxis on long term clinical impact of malaria infection among HIV infected adults on successful ART.
HIV / AIDS HUMAN IMMUNODEFICIENCY Virus (HIV) ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
ART was initiated when indicated by WHO and national guidelines
Seroprevalence, prevalence, type and factors associated with HPV infection at multiple sites in young HIV-positive MSM On behalf of the HPV MAPS Research.
What is HIV? Human Immunodeficiency Virus.
Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.
Validating Definitions of Antiretroviral Treatment Failure in Malawi
HIV and AIDS.
A. Stepanov, A. Kruk, N. Polovinkina, A. Vinogradova
What is HIV? Human Immunodeficiency Virus.
What is HIV? Human Immunodeficiency Virus.
What is HIV? Human Immunodeficiency Virus.
What is HIV? Human Immunodeficiency Virus.
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Presentation transcript:

Institutes: Ukrainian Medical and Dental Academy, Regional HIV/AIDS Prevention and Control Center, Poltava Ukraine Toll-like receptor 4 polymorphism influence on the development of opportunistic diseases in HIV-infected patients The presenting author is Tetiana Kyrychenko Tetiana Kyrychenko Authors: G. Dubynska, T.Koval, I.Kaidashev, V.Korshenko

Ukraine has one of the fastest growing HIV/AIDS epidemics in the world and the highest in all of Europe. Late 2011 Ukraine numbered 210,000 HIV- positive persons. Dynamics of officially registered new cases of HIV- infection in Ukraine (on 100 thousand population)

Toll-like receptors (TLRs) have a key role in innate immunity and mutations in the genes encoding these receptors have been associated with increased or decreased susceptibility to infections.

 Objectives:  to study the prevalence of TLR4 Asp299Gly SNP among the healthy and HIV-positive persons in Ukraine ;  to find out HIV clinical manifestations depending on TLR4 genotype variants. Asp299Gly, A>G chromosome 9q32–33

Methods Patients. The study included 180 antiretroviral treatment-naive HIV-1 infected patients. Patients. The study included 180 antiretroviral treatment-naive HIV-1 infected patients. The stage of the disease was recorded in accordance with the expanded European AIDS case definition. Laboratory procedures. Laboratory procedures. Routine CD-4 cell count was determined using conventional flow cytometry with fresh blood samples from all patients. Plasma HIV-RNA was also routinely measured by the polymerase chain reaction (PCR) (Real time HIV-1, Abbout). TLR4 genotyping was performed by real- time PCR using oligonucleotide primers Tercik PCR system, DNA-technology, Moscow) TLR4 genotyping was performed by real- time PCR using oligonucleotide primers (Tercik PCR system, DNA-technology, Moscow)

Characteristic of a Cohort of 180 patients infected with HIV-1 and studied in Relation to SNP of TLR4 Characteristic Wild type (AA, n=165) Asp299Gly heterozygous (AG, n=15) Male-to-female ratio 98:67 10:5 Ageª, mean years ± standard deviation 35,21±0,5135,13±1,33 Nadir CD-4 cell countª, mean cell/mm³ ± standard deviation 259,52±16,2233,6±30,38 Maximum viral loadª, median copies/mL Clinical stage(%) ABC 11 (6,6) 72 (43,7) 82 (49,7) 2(13,3)2(13,3)11(73,4)

Historyof opportunistic infections in 180 HIV-infected patients History of opportunistic infections in 180 HIV-infected patients

Historyof opportunistic infections in 180 HIV-infected patients in relation to SNP of the Toll-like receptor 4 gene (No. (%) of patients) History of opportunistic infections in 180 HIV-infected patients in relation to SNP of the Toll-like receptor 4 gene (No. (%) of patients) Variable Wild type (AA, n=165) Asp299Gly heterozygous (AG, n=15) p Mycobacterium tuberculosis, pulmonary or extrapulm. 59 (35.7) 11 (73.3) 0.007* Bacterial pneumonia, recurrent 42 (25.5) 8 (53.3) 0.021* Hairy leukoplakia, oral 51 (30.9) 9 (60) 0.022* Herpes zoster (shingles), involving two or more episodes or at least one dermatome 29 (17.6) 7 (46.7) 0.007* AG compared to AA, Mann-Whitney U-test *AG compared to AA, Mann-Whitney U-test

Historyof opportunistic infections in 180 HIV-infected patients in relation to SNP of the Toll-like receptor 4 gene (No. (%) of patients) History of opportunistic infections in 180 HIV-infected patients in relation to SNP of the Toll-like receptor 4 gene (No. (%) of patients) Variable Wild type (AA, n=165) Asp299Gly heterozygous (AG, n=15) p Chronic hepatitis C 80 (48.5) 12 (80) 0.018* Candidiasis, oropharyngeal or esophageal 78 (47.3) 8 (53.3) >0.05 Wasting syndrome caused by HIV (involuntary weight loss >10% of baseline body weight) associated with either chronic diarrhea or chronic weakness and documented fever for ≥1 month) 42 (25.5) 6 (40) >0.05 Herpes simplex: chronic ulcers (>1 month in duration) 28 (17) 5 (33.3) >0.05 Any 19 (11.5) 3 (20) >0.05 AG compared to AA, Mann-Whitney U-test *AG compared to AA, Mann-Whitney U-test

Distribution of the 299 alleles of the patients when they were grouped by CD-4 T-cell counts equal to or above and below 350, cells/mm³, respectively Only patients with CD4 T-cell counts above 200cells/mm³ had the prevalence of the Asp299Gly polymorphism (12%) *Only patients with CD4 T-cell counts above 200cells/mm³ had the prevalence of the Asp299Gly polymorphism (12%) significantly higher than patients with CD4 T-cell counts below than 200 cells/mm³ (3.7%), p<0.05

Detection of opportunistic infections in HIV- infected patients with different levels of CD4 (No. (%) of patients) CD-4 T-cell counts /mm³ < >350 TLR-4 genotype AA,n=31AG,n=3AA,n=102AG,n=9AA,n=32AG,n=3 Tuberculosis20(64.5)3(100)34(33.3)6(66.7)*5(15.6)2(66.7)* Toxoplasmosis12(38.8)3(100)*0(0)1(11.1)*00 Herpes zoster 2(6.5)1(33.3)24(23.6)5(55.6)*3(9.3)1(33.3) Pneumonia10(32.3)1(33.3)22(21.6)5(55.6)*10(31)2(66.7) AG compared to AA, X²-test, p<0.05 * AG compared to AA, X²-test, p<0.05

Conclusions  This study suggests a grater risk for development of active tuberculosis, bacterial pneumonia, herpes zoster, hairy leukoplakia, toxoplasmosis of brain, chronic hepatitis C in patients with the Asp299Gly TLR4 polymorphism  our results demonstrate the impact of a TLR4 genetic polymorphism on development of opportunistic infections for CD4 levels more than 100.

Acknowledgments  G.Dubynska, prof., department of infectious diseases, Ukrainian Medical and Dental Academy, Poltava, Ukraine  T.Koval, prof., department of infectious diseases, Ukrainian Medical and Dental Academy, Poltava, Ukraine  I. Kajdashev, prof., chair of research department, Ukrainian Medical and Dental Academy, Poltava, Ukraine  V.Korshenko, chief doctor of Regional centre of HIV/AIDS Poltava, Ukraine